A Study to Evaluate Efficacy and Safety of Oxycodone/Naloxone Compared to OxyContin in Korean Cancer Patients
NCT ID: NCT01313780
Last Updated: 2017-12-22
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
128 participants
INTERVENTIONAL
2011-05-31
2014-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To prove non-inferiority of Targin compared to Oxycontin in terms of change of pain intensity
1. Primary objective: Change of pain intensity (NRS 0-10) score (average pain over 24 hours obtained each evening) within 4 weeks
2. Secondary objectives: Bowel Habit (worsening/no change/improving), Total dose and frequency of rescue medication, Quality of Life (QOL; EORTC QLQ-C30), Duration to need of laxative use and Adverse events
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
'Oxycodone/Naloxone'
Trade name is Targin(fixed combination drug).
Oxycodone/Naloxone
Dose and administration : Upto 40mg B.I.D per daily.
Oxycodone
Trade name is Oxycontin(single compound).
Oxycodone(single compound)
Dose and administration : Upto 40mg B.I.D per daily.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oxycodone/Naloxone
Dose and administration : Upto 40mg B.I.D per daily.
Oxycodone(single compound)
Dose and administration : Upto 40mg B.I.D per daily.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Cancer related pain that requires treatment with continuous around-the-clock strong opioid analgesic
3. Moderate to severe pain intensity(NRS pain score 4)
4. Opioid naïve patients or patients not treated with strong opioids(except PRN) within 4 weeks or patients who has been on weak opioids
5. Subject who provide signed and dated written voluntary informed consent
Exclusion Criteria
* women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner
* women shoes partners have been sterilized by vasectomy or other means
* two birth control methods. The two methods can be a double barrier method or a barrier method plus a hormonal method. Adequate barrier methods of contraception include: diaphragm, condom (by the partner), intrauterine device (copper or hormonal), sponge or spermicide. Hormonal contraceptives include any marketed contraceptive agent that includes an estrogen and/or a progestational agent.
2. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive urine pregnancy test.
3. Have previously received treatment with Targin or Oxycontin within 4weeks(28days) of screening periods(including PRN)
4. If subjects started first cycle of chemotherapy during the 2 weeks before the screening visit or during the study, they should be excluded from the study.
And If the chemotherapy regimen or dosage to be planned to change during the study, the subjects should be excluded from the study.
5. Patient who is administered laxatives with stable dose for more than 1 week
6. Patient with evidence of significant structural/functional abnormalities of GI tract which is not appropriate for oral medicine administration. Any history of hypersensitivity to Oxycodone and Naloxone
7. Patients with significant respiratory depression
8. Patients with acute or severe bronchial asthma or hypercarbia
9. Any patient who has or is suspected of having paralytic ileus
10. Severe Chronic obstructive pulmonary disease, pulmonary heart disease
11. Targin product contains lactose. Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not take
12. Patients with moderate and severe hepatic impairment
13. Abnormal aspartate aminotransferase (AST; SGOT), alanine aminotransferase (ALT; SGPT), or alkaline phosphatase levels (\>2.5 times the upper limit of normal, it is allowed \>5 times the upper limit of normal in case of transition in liver) or an abnormal total bilirubin and/or creatinine level(s) (greater than 1.5 times the upper limit of normal)
14. Any situation where opioids are contraindicated
15. Major surgery within 1 month prior to screening or planned surgery
16. Mainly pain originated other than cancer or cancer related conditions (eg. Musculoskeletal pain, inflammatory pain, diabetic polyneuropathy)
17. Patients with known or suspected unstable brain metastases or spinal cord compression that may require changes in steroid treatment throughout the duration of the study
18. Patients with uncontrolled seizures
19. Requiring interventional treatment for pain such as neurodestructive procedure or regional infusion
20. With a history of alcohol abuse within 6 months of screening
21. With a history of illicit drug abuse within 6 months of screening
22. Patients with increased intracranial pressure
23. In the investigator's opinion, subjects who are receiving hypnotics or other central nervous system (CNS) depressants that may pose a risk of additional CNS depression with opioid study medication
24. Patients with myxoedema, not adequately treated hypothyroidism or Addison's disease
25. Patients receiving opioid substitution therapy for opioid addiction (e.g. methadone or buprenorphine)
26. Patients with evidence of clinically significant gastrointestinal disease (e.g. paralytic ileus, peritoneal carcinosis), significant structural abnormalities of the gastrointestinal tract (e.g. scarring, obstruction etc) either related or not related to the underlying cancer or disease progression
27. Patients suffering from diarrhea and/or opioid withdrawal
28. With a disability that may prevent the patient from completing all study requirements and in particular, interfere with 24hrs pain intensity score
29. Clinically significant impairment of cardiovascular, respiratory and renal function
30. Patient who needs acute dose titration or whose pain intensity fluctuate significantly in a short period according to investigator's judgment
31. Having used other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mundipharma Korea Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kim, M.D
Role: PRINCIPAL_INVESTIGATOR
Asan Medical Center
Ahn, M.D
Role: PRINCIPAL_INVESTIGATOR
Samsung Medical Center
Kim, M.D
Role: PRINCIPAL_INVESTIGATOR
National Cancer Center
Kim, M.D
Role: PRINCIPAL_INVESTIGATOR
SMG-SNU Boramae Medical Center
Lee, M.D
Role: PRINCIPAL_INVESTIGATOR
Shinchone Yonsei Severance Medical Center
Kang Jugnhoon
Role: PRINCIPAL_INVESTIGATOR
Kyungsang University Hospital
Lee Kyunghee, MD
Role: PRINCIPAL_INVESTIGATOR
Youngnam Univ. Hospital
Yoon Hwanjung, MD
Role: PRINCIPAL_INVESTIGATOR
Chungnam University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AMC
Seoul, Pungnap-dong, South Korea
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lee KH, Kim TW, Kang JH, Kim JS, Ahn JS, Kim SY, Yun HJ, Eum YJ, Koh SA, Kim MK, Hong YS, Kim JE, Lee GW. Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial. Chin J Cancer. 2017 Sep 11;36(1):74. doi: 10.1186/s40880-017-0241-4.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OXN10-KR-002
Identifier Type: -
Identifier Source: org_study_id